"Cytomegalovirus" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS.
| Descriptor ID |
D003587
|
| MeSH Number(s) |
B04.280.382.150.150
|
| Concept/Terms |
Cytomegalovirus- Cytomegalovirus
- Cytomegaloviruses
- Salivary Gland Viruses
- Salivary Gland Virus
- Virus, Salivary Gland
- Viruses, Salivary Gland
|
Below are MeSH descriptors whose meaning is more general than "Cytomegalovirus".
Below are MeSH descriptors whose meaning is more specific than "Cytomegalovirus".
This graph shows the total number of publications written about "Cytomegalovirus" by people in this website by year, and whether "Cytomegalovirus" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 2 | 3 |
| 1995 | 2 | 2 | 4 |
| 1996 | 3 | 5 | 8 |
| 1997 | 1 | 2 | 3 |
| 1998 | 0 | 4 | 4 |
| 1999 | 0 | 1 | 1 |
| 2000 | 2 | 4 | 6 |
| 2001 | 0 | 2 | 2 |
| 2002 | 3 | 4 | 7 |
| 2003 | 4 | 3 | 7 |
| 2004 | 5 | 5 | 10 |
| 2005 | 3 | 4 | 7 |
| 2006 | 9 | 3 | 12 |
| 2007 | 4 | 3 | 7 |
| 2008 | 5 | 4 | 9 |
| 2009 | 3 | 3 | 6 |
| 2010 | 3 | 2 | 5 |
| 2011 | 5 | 1 | 6 |
| 2012 | 6 | 4 | 10 |
| 2013 | 5 | 4 | 9 |
| 2014 | 5 | 3 | 8 |
| 2015 | 5 | 3 | 8 |
| 2016 | 6 | 4 | 10 |
| 2017 | 1 | 3 | 4 |
| 2018 | 7 | 5 | 12 |
| 2019 | 9 | 3 | 12 |
| 2020 | 3 | 8 | 11 |
| 2021 | 6 | 2 | 8 |
| 2022 | 1 | 3 | 4 |
| 2023 | 1 | 4 | 5 |
| 2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cytomegalovirus" by people in Profiles.
-
Current and Emerging Antiviral Agents in the Prevention and Treatment of Cytomegalovirus in Pediatric Transplant Recipients. J Pediatric Infect Dis Soc. 2024 Feb 28; 13(Supplement_1):S14-S21.
-
Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. J Infect Dis. 2024 Feb 14; 229(2):413-421.
-
A small molecule exerts selective antiviral activity by targeting the human cytomegalovirus nuclear egress complex. PLoS Pathog. 2023 Nov; 19(11):e1011781.
-
CMV prevention strategies in allogeneic hematopoietic cell transplantation; the role of prophylaxis and pre-emptive monitoring in the era of letermovir. Transpl Infect Dis. 2023 Nov; 25 Suppl 1:e14171.
-
Extended duration letermovir in allogeneic hematopoietic stem cell transplant. Transpl Immunol. 2023 12; 81:101936.
-
Body surface area compared to body weight dosing of valganciclovir is associated with increased toxicity in pediatric solid organ transplantation recipients. Am J Transplant. 2023 Dec; 23(12):1961-1971.
-
Another tool against cytomegalovirus after allogeneic hematopoietic cell transplantation. J Clin Invest. 2023 05 15; 133(10).
-
Cancer risk associated with cytomegalovirus infection among solid organ transplant recipients in the United States. Cancer. 2022 11 15; 128(22):3985-3994.
-
Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial. Clin Infect Dis. 2022 09 10; 75(4):690-701.
-
CXCR6+ and NKG2C+ Natural Killer Cells Are Distinct With Unique Phenotypic and Functional Attributes Following Bone Marrow Transplantation. Front Immunol. 2022; 13:886835.